uniQure NV started an underwritten public offering of its ordinary shares worth $200 million.
The Amsterdam-based biotechnology company, which develops and markets gene therapies, also plans to give underwriters a 30-day option to purchase additional ordinary shares worth $30 million.
Goldman Sachs & Co. LLC and SVB Leerink are acting as joint book-running managers, Stifel is acting as book-running manager while Cantor Fitzgerald & Co. and SunTrust Robinson Humphrey are co-lead managers. H.C. Wainwright & Co. is co-manager for the offering.
